167 related articles for article (PubMed ID: 9052418)
1. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
Br J Cancer; 1997; 75(4):602-5. PubMed ID: 9052418
[TBL] [Abstract][Full Text] [Related]
2. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
Saarto T; Vehmanen L; Elomaa I; Välimäki M; Mäkelä P; Blomqvist C
Br J Cancer; 2001 Apr; 84(8):1047-51. PubMed ID: 11308252
[TBL] [Abstract][Full Text] [Related]
3. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients.
Marttunen MB; Hietanen P; Tiitinen A; Ylikorkala O
J Clin Endocrinol Metab; 1998 Apr; 83(4):1158-62. PubMed ID: 9543133
[TBL] [Abstract][Full Text] [Related]
4. Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene.
Tiitinen A; Nikander E; Hietanen P; Metsä-Heikkilä M; Ylikorkala O
Maturitas; 2004 Jul; 48(3):321-7. PubMed ID: 15207898
[TBL] [Abstract][Full Text] [Related]
5. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.
Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
J Clin Oncol; 1997 Apr; 15(4):1341-7. PubMed ID: 9193325
[TBL] [Abstract][Full Text] [Related]
6. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.
Vehmanen L; Saarto T; Elomaa I; Mäkelä P; Välimäki M; Blomqvist C
Eur J Cancer; 2001 Dec; 37(18):2373-8. PubMed ID: 11720830
[TBL] [Abstract][Full Text] [Related]
7. Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer.
Zidan J; Keidar Z; Basher W; Israel O
Med Oncol; 2004; 21(2):117-21. PubMed ID: 15299183
[TBL] [Abstract][Full Text] [Related]
8. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women.
Marttunen MB; Cacciatore B; Hietanen P; Pyrhönen S; Tiitinen A; Wahlström T; Ylikorkala O
Br J Cancer; 2001 Apr; 84(7):897-902. PubMed ID: 11286468
[TBL] [Abstract][Full Text] [Related]
9. Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer.
Marttunen MB; Hietanen P; Titinen A; Roth HJ; Viinikka L; Ylikorkala O
Calcif Tissue Int; 1999 Nov; 65(5):365-8. PubMed ID: 10541761
[TBL] [Abstract][Full Text] [Related]
10. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial.
Tominaga T; Kimijima I; Kimura M; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
Jpn J Clin Oncol; 2010 Jul; 40(7):627-33. PubMed ID: 20382637
[TBL] [Abstract][Full Text] [Related]
11. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.
Powles TJ; McCloskey E; Paterson AH; Ashley S; Tidy VA; Nevantaus A; Rosenqvist K; Kanis J
J Natl Cancer Inst; 1998 May; 90(9):704-8. PubMed ID: 9586668
[TBL] [Abstract][Full Text] [Related]
12. Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer.
Rizzoli R; Forni M; Schaad MA; Slosman DO; Sappino AP; Garcia J; Bonjour JP
Bone; 1996 Jun; 18(6):531-7. PubMed ID: 8805993
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
Vehmanen L; Elomaa I; Blomqvist C; Saarto T
J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
15. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.
Saarto T; Blomqvist C; Ehnholm C; Taskinen MR; Elomaa I
J Clin Oncol; 1996 Feb; 14(2):429-33. PubMed ID: 8636753
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.
Holli K; Valavaara R; Blanco G; Kataja V; Hietanen P; Flander M; Pukkala E; Joensuu H
J Clin Oncol; 2000 Oct; 18(20):3487-94. PubMed ID: 11032589
[TBL] [Abstract][Full Text] [Related]
17. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years.
Love RR; Barden HS; Mazess RB; Epstein S; Chappell RJ
Arch Intern Med; 1994 Nov; 154(22):2585-8. PubMed ID: 7979855
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density following surgical oophorectomy and tamoxifen adjuvant therapy for breast cancer.
Love RR; Young GS; Laudico AV; Van Dinh N; Uy GB; Quang le H; De La Peña AS; Dofitas RB; Bisquera OC; Siguan SS; Salvador JD; Mirasol-Lumague MR; Navarro NS; Linh ND; Jarjoura D
Cancer; 2013 Nov; 119(21):3746-52. PubMed ID: 23963821
[TBL] [Abstract][Full Text] [Related]
19. The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
Jones S; Stokoe C; Sborov M; Braun M; Ethirajan S; Kutteh L; Pippen J; Patel M; Paul D; Blum JL; Holmes FA; Myron MC; Cantrell J; Hartung NL; Look RM; Di Salle E; Davis JC; Ilegbodu D; Asmar L
Clin Breast Cancer; 2008 Dec; 8(6):527-32. PubMed ID: 19073509
[TBL] [Abstract][Full Text] [Related]
20. Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients.
Bertelli G; Queirolo P; Vecchio S; Angiolini C; Bergaglio M; Del Mastro L; Signorini A; Valenzano M; Venturini M
Anticancer Res; 2000; 20(5C):3659-61. PubMed ID: 11268435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
